{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:10:46Z","timestamp":1791295846707,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81071371"],"award-info":[{"award-number":["81071371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.antiviral.2013.04.009","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T14:39:52Z","timestamp":1366209592000},"page":"373-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"98","author":[{"given":"Qianqian","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.04.009_b0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.12816\/0006339","article-title":"Role of statins in the treatment of chronic hepatitis C virus infection","volume":"42","author":"Abd-Eldaem","year":"2012","journal-title":"J. Egypt. Soc. Parasitol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0010","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.14309\/00000434-201010001-00313","article-title":"Statin Th erapy decreases risk of hepatic steatosis and lobular Infl ammation in patients with nonalcoholic fatty liver disease","volume":"105","author":"Abdelmalek","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0015","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1517\/14656566.2011.597742","article-title":"Metabolic alterations and chronic hepatitis C: treatment strategies","volume":"12","author":"Adinolfi","year":"2011","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.antiviral.2013.04.009_b0020","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1128\/JVI.02530-07","article-title":"Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection","volume":"82","author":"Aizaki","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1440-1746.2012.07267.x","article-title":"Combination of fluvastatin with pegylated interferon\/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b","volume":"28","author":"Atsukawa","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0030","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1572-0241.2008.01876.x","article-title":"Fluvastatin inhibits hepatitis C replication in humans","volume":"103","author":"Bader","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(12)63641-5","article-title":"A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naive genotype one hepatitis C patients","volume":"142","author":"Bader","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0040","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cid\/cir774","article-title":"Boceprevir and telaprevir in the management of hepatitis C virus-infected patients","volume":"54","author":"Butt","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.04.009_b0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.22916","article-title":"Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development","volume":"50","author":"Delang","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0050","doi-asserted-by":"crossref","first-page":"S456","DOI":"10.1016\/S0016-5085(11)61875-1","article-title":"Peginterferon \u03b1-2a, ribavirin and fluvastatin combination therapy for chronic hepatitis C in children and adolescents","volume":"140","author":"Etani","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0315","doi-asserted-by":"crossref","unstructured":"Florentin, M., Liberopoulos, E. N., Rizos, C. V., Kei, A. A., Liamis, G., Kostapanos, M. S.,Elisaf, M. S. 2012. Colesevelam Plus Rosuvastatin 5 mg\/Day Versus Rosuvastatin 10 mg\/Day Alone on Markers of Insulin Resistance in Patients with Hypercholesterolemia and Impaired Fasting Glucose. Metab. Syndr. Relat. Disord. http:\/\/dx.doi.org\/10.1089\/met.2012.0103.","DOI":"10.1089\/met.2012.0103"},{"key":"10.1016\/j.antiviral.2013.04.009_b0060","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.3748\/wjg.15.5020","article-title":"Do statins reduce hepatitis C RNA titers during routine clinical use?","volume":"15","author":"Forde","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0065","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/JVI.02053-07","article-title":"Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion","volume":"82","author":"Gastaminza","year":"2008","journal-title":"J. Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.04.009_b0070","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0168-8278(11)60012-3","article-title":"Potential enhancement of both early (EVR) and sustained(SVR) virological response by fluvasatin in chronic hepatitis C treated standard PegIFN-ribavirin therapy. A pilot study","volume":"54","author":"Georgescu","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0075","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0080","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/(SICI)1097-0258(19961215)15:23<2493::AID-SIM381>3.0.CO;2-C","article-title":"Models for estimating the number of unpublished studies","volume":"15","author":"Gleser","year":"1996","journal-title":"Stat. Med."},{"key":"10.1016\/j.antiviral.2013.04.009_b0085","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1006\/cyto.1999.0504","article-title":"Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha","volume":"11","author":"Grungreiff","year":"1999","journal-title":"Cytokine"},{"key":"10.1016\/j.antiviral.2013.04.009_b0090","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S1542-3565(05)00246-6","article-title":"Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C","volume":"3","author":"Harrison","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0095","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hep.23787","article-title":"Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy","volume":"52","author":"Harrison","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0100","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/nm.2238","article-title":"Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1","volume":"16","author":"Herker","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2013.04.009_b0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hep.21232","article-title":"Different anti-HCV profiles of statins and their potential for combination therapy with interferon","volume":"44","author":"Ikeda","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.antiviral.2013.04.009_b0115","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.antiviral.2013.04.009_b0120","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.0409834102","article-title":"Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids","volume":"102","author":"Kapadia","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.04.009_b0125","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.cgh.2006.03.014","article-title":"Incidence of statin hepatotoxicity in patients with hepatitis C","volume":"4","author":"Khorashadi","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0130","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s00535-010-0203-y","article-title":"Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH","volume":"45","author":"Kimura","year":"2010","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0135","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.25653","article-title":"Review and management of drug interactions with boceprevir and telaprevir","volume":"55","author":"Kiser","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0140","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2893.2011.01584.x","article-title":"An open-label randomized controlled study of pegylated interferon\/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin","volume":"19","author":"Kondo","year":"2012","journal-title":"J. Viral. Hepat."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.04.009_b0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2013.04.009_b0150","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1128\/AAC.00653-11","article-title":"Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.04.009_b0155","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","article-title":"Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial","volume":"46","author":"Lewis","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0160","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1440-1746.2012.07232.x","article-title":"Potential for statins in the chemoprevention and management of hepatocellular carcinoma","volume":"27","author":"Lonardo","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0165","doi-asserted-by":"crossref","first-page":"e26637","DOI":"10.1371\/journal.pone.0026637","article-title":"Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry","volume":"6","author":"Maillard","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2013.04.009_b0170","first-page":"92","article-title":"Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with alpha-interferon and ribavirin: rosuvastatin reduces NAFLD in HCV patients","volume":"11","author":"Malaguarnera","year":"2011","journal-title":"Hepat. Mon."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.04.009_b0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000315225","article-title":"Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis\/liver cirrhosis","volume":"78","author":"Masuzaki","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0180","first-page":"1704","article-title":"Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C","volume":"56","author":"Mihaila","year":"2009","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0185","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2013.04.009_b0190","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2893.2009.01187.x","article-title":"In vivo effects of fluvastatin on HCV replication in HIV-1 coinfected subjects","volume":"17","author":"Milazzo","year":"2010","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2013.04.009_b0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2893.2009.01104.x","article-title":"Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients","volume":"16","author":"Milazzo","year":"2009","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2013.04.009_b0200","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jac\/dkq002","article-title":"Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV\/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study","volume":"65","author":"Milazzo","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.04.009_b0205","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4","article-title":"Low density lipoprotein receptor as a candidate receptor for hepatitis C virus","volume":"57","author":"Monazahian","year":"1999","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0210","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/gut.2009.192732","article-title":"Abnormalities of lipid metabolism in hepatitis C virus infection","volume":"59","author":"Negro","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2013.04.009_b0215","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0220","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/JVI.80.5.2418-2428.2006","article-title":"Association between hepatitis C virus and very-low-density lipoprotein (VLDL)\/LDL analyzed in iodixanol density gradients","volume":"80","author":"Nielsen","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0225","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/hep.21554","article-title":"Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial","volume":"45","author":"O\u2019Leary","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(12)63724-X","article-title":"Statin therapy enhances response to pegylated interferon and ribavirin in genotype 1 chronic hepatitis c patients: reults from a propensity matched veteran cohort","volume":"142","author":"Oni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2009.08.037","article-title":"Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor","volume":"394","author":"Owen","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0240","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2893.2010.01310.x","article-title":"Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C","volume":"18","author":"Patel","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2013.04.009_b0245","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more","volume":"52","author":"Pearlman","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.04.009_b0250","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2003.08.007","article-title":"Hepatitis C virus infection and liver steatosis","volume":"60","author":"Ramalho","year":"2003","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.04.009_b0255","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMcp1006613","article-title":"Clinical practice. Chronic hepatitis C infection","volume":"364","author":"Rosen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.04.009_b0260","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/COH.0b013e32834b54dc","article-title":"Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions","volume":"6","author":"Seden","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2013.04.009_b0265","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0270","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000213504","article-title":"An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads","volume":"52","author":"Sezaki","year":"2009","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0320","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clinre.2012.07.002","article-title":"Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)","volume":"37","author":"Sheridan","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol"},{"key":"10.1016\/j.antiviral.2013.04.009_b0280","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jhep.2011.04.024","article-title":"Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study","volume":"56","author":"Shimada","year":"2012","journal-title":"J Hepatol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00042737-200502000-00004","article-title":"Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C","volume":"17","author":"Thomopoulos","year":"2005","journal-title":"Eur. J. Gastroen Hepat."},{"key":"10.1016\/j.antiviral.2013.04.009_b0325","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.2012.44.6831","article-title":"Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection","volume":"31","author":"Tsan","year":"2013","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.antiviral.2013.04.009_b0295","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1053\/j.gastro.2007.07.007","article-title":"Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse","volume":"133","author":"Vanwolleghem","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.04.009_b0300","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.molcel.2005.04.004","article-title":"Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication","volume":"18","author":"Wang","year":"2005","journal-title":"Mol. Cell."},{"key":"10.1016\/j.antiviral.2013.04.009_b0305","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.coviro.2012.08.008","article-title":"Clinical relevance of HCV antiviral drug resistance","volume":"2","author":"Welsch","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2013.04.009_b0310","doi-asserted-by":"crossref","first-page":"15865","DOI":"10.1073\/pnas.2237238100","article-title":"Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation","volume":"100","author":"Ye","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T15:21:13Z","timestamp":1562944873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0166354213000958"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.04.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}